Konstantin Penkov

INDUCE-3: A Gerandomiseerde Fase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent...

Clinical cancer research : an official journal of the American Association for Cancer Research · 16 maart 2026

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monothera...

European journal of cancer (Oxford, England : 1990) · 9 september 2025

Encorafenib plus binimetinib plus pembrolizumab bij BRAF-gemuteerd melanoom: STARBOARD veiligheid

European journal of cancer (Oxford, England : 1990) · 2024-12

Ribociclib plus endocriene therapie versus chemotherapie bij HR-positief mammacarcinoom: RIGHT Choice definitief

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 augustus 2024

Bempegaldesleukin plus nivolumab versus sunitinib/cabozantinib bij mRCC: PIVOT-09 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 augustus 2024

Cemiplimab plus chemotherapie bij gevorderd NSCLC: EMPOWER-Lung 3 tweejaars

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-06

Lorlatinib intracraniële werkzaamheid bij ALK-positief NSCLC: CROWN post-hoc

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 november 2022

Rovalpituzumab tesirine versus topotecan als tweedelijns bij DLL3-positief SCLC: TAHOE fase III

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-09

Veliparib plus carboplatine-etoposide bij uitgebreid SCLC: fase II

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 juli 2021

Avelumab plus axitinib versus sunitinib bij gevorderd RCC: JAVELIN Renal 101 fase III

The New England journal of medicine · 21 maart 2019

Publicaties op Oncologisch.com